参考文献/References:
[1] Podgorsak EB. Radiation oncology physics:a handbook for teachers and students[M]. Vienna:International Atomic Erergy Agency,2005:463-464.
[2] Pantelis E,Papagiannis P,Anagnostopoulos G,et al. Evaluation of a TG-43 compliant analytical dosimetry model in clinical 192Ir HDR brachytherapy treatment planning and assessment of the significance of source position and catheter reconstruction uncertainties[J].Phys Med Biol,2004,49(1):55-67.
[3] Wilkinson DA. High dose rate (HDR)brachytherapy quality assurance:a practical guide[J/OL]. Biomed Imaging Interv J,2006,2(2):e34. http://www.biij.org/2006/2/e34/default.asp.
[4] Venselaar J,Pérez-Calatayud J,A practical to quality control of brachytherapy equipment[MJ. Brussels(Belgium):European Society for Therapeutic Radiology and Oncology,2004:224.
[5] Kubo HD,Glasgow GP,Pethel TD,et al. High dose-rate brachytherapy treatment delivery:report of the AAPM Radiation Therapy Committee Task Group No.59[J]. Med Phys,1998,25(4):375-403.
[6] Nath R,Anderson LL,Luxton G,et al. Dosimetry of interstitial brachytherapy sources:recommendations of the AAPM Radiation Therapy Committee Task Group No.43. American Association of Physieists in Medicine[J]. Med Phys,1995,22(2):209-234.
[7] Bochud F,Leemann B,Linder R,et al. Dosimetry and quality assurance in high dose rate brachytherapy with Iridium-192[M]. Swiss:Swiss Society for Radiobiology and Medical Physics,2005:5-6.
[8] Rivard MJ,Coursey BM,DeWerd LA,et al. Update of AAPM Task Group No.43 Report:A revised AAPM protocol for brachytherapy dose calculations[J]. Med Phys,2004,31(3):633-674.
相似文献/References:
[1]田琦,张丽花,蒋宁一.甲状腺癌131I治疗后合并骨髓增生异常综合征一例[J].国际放射医学核医学杂志,2016,40(3):235.[doi:10.3760/cma.j.issn.1673-4114.2016.03.014]
[2]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[3]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[7]侯朝华,霍彬,宋杨.组织间近距离放射性粒子植入治疗肿瘤的进展[J].国际放射医学核医学杂志,2015,39(4):348.[doi:10.3760/cma.j.issn.1673-4114.2015.04.016]
Hou Zhaohua,HuoBin,SongYang.Organizational close radioactive seed implantation therapy in treating tumor progression[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):348.[doi:10.3760/cma.j.issn.1673-4114.2015.04.016]
[8]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[9]张俊涛.晚期肺癌125I粒子植入治疗近期疗效观察[J].国际放射医学核医学杂志,2014,38(2):94.[doi:10.3760/cma.j.issn.1673-4114.2014.02.006]
Zhang Juntao.Short-term efficacy of 125I seeds implantation in the treatment of advanced lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):94.[doi:10.3760/cma.j.issn.1673-4114.2014.02.006]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]